Immunotherapy for penile cancer
- PMID: 28883996
- PMCID: PMC5583688
- DOI: 10.4155/fsoa-2017-0031
Immunotherapy for penile cancer
Keywords: HPV; environment; immunotherapy; nivolumab; penile cancer.
Conflict of interest statement
Financial & competing interests disclosure The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. No writing assistance was utilized in the production of this manuscript.
References
-
- Forman D, De Martel C, Lacey CJ, et al. Global burden of human papillomavirus and related diseases. Vaccine. 2012;30(Suppl. 5):F12–F23. - PubMed
-
- Lont AP, Kroon BK, Horenblas S, et al. Presence of high-risk human papillomavirus DNA in penile carcinoma predicts favorable outcome in survival. Int. J. Cancer. 2006;119(5):1078–1081. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources